u/Joehax00 · 54d ago2 prior · awaiting results
SLGL - Sol-Gel Technologies: catalyst-driven dermatology biotech, Gorlin Phase 3 readout Q4 2026. A major 10% holder has been buying.
Sol-Gel is a binary biotech play on a Q4 2026 Phase 3 readout for SGT-610 in Gorlin syndrome with no approved therapy to prevent basal cell carcinomas. A positive result could re-rate the asset to $600m+ peak sales with patent protection to 2044, and a major 10% insider holder (Opaleye) has consistently bought through volatility, adding conviction to the thesis.